Clinical Trial Update: A Study for Post-Marketing Surveillance of Nesina® Tablet Monotherapy or Combination Therapy in Participants With Type 2 Diabetes (T2DM) in South Korea

View source ↗

Summary

Post-marketing surveillance trial for Nesina (alogliptin) monotherapy or in combination for type 2 diabetes in South Korea has completed; results posted in 2022…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Nesina (alogliptin)

Snippet

Sponsor: Takeda | Conditions: Type 2 Diabetes Mellitus | Status: COMPLETED | Results posted: 2022-04-05